| Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share |
The following table reconciles the numerator and denominator in the computations of basic and diluted loss per share:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
March 31, | | Six Months Ended
March 31, | | 2026 | | 2025 | | 2026 | | 2025 | | Numerator: | | | | | | | | | Consolidated net loss | $ | (32,467) | | | $ | (14,866) | | | $ | (60,845) | | | $ | (42,496) | | | | | | | | | | | Denominator: | | | | | | | | | Weighted-average shares outstanding - Basic (in thousands) | 34,653 | | 33,995 | | 34,510 | | 30,540 | | Weighted-average shares outstanding - Diluted (in thousands) | 34,653 | | 33,995 | | 34,510 | | 30,540 | Anti-dilutive common share equivalents1 | 9,885 | | 10,797 | | 9,885 | | 10,797 | 1As of March 31, 2026, anti-dilutive common share equivalents are comprised of stock options, restricted stock units, 2,859,306 common shares issuable upon conversion of the Notes and 3,034,124 common shares issuable upon the exercise of the Warrants. As of March 31, 2025, anti-dilutive common share equivalents are comprised of stock options, restricted stock units, restricted stock awards, 2,859,306 common shares issuable upon conversion of the Notes and 3,034,124 common shares issuable upon the exercise of the Warrants. These common share equivalents were outstanding for the periods presented, but were not included in the computation of diluted net loss per share for those periods because their inclusion would have had an anti-dilutive effect. |
|